Abstract
Objective High flow nasal cannula therapy (HFNC) may increase aerosol generation, putting health care workers at increased risk of infection, including from SARS-CoV-2. This study examined whether use of HFNC increases near-field aerosols and if there is a relationship between flow rate and near-field aerosol concentrations.
Patients and Methods Subjects between 30 days and 2 years of age were enrolled. Each child received HFNC therapy at different flow rates over time. Three sampling stations with particle counters were deployed to measure aerosol generation and dispersion in the room: station one within 0.5 m of the subject, station two at 2 m, and station three on the other side of the room. We also measured carbon dioxide (CO2) and relative humidity. Station three (far-field) measurements were used to adjust the station one (near-field) measurements for room conditions.
Results We enrolled ten children ranging from 6-24 months (median 9 months), two with respiratory illness. Elevated CO2 indicated the near-field measurements were in the breathing plane of the subjects. Near-field breathing plane concentrations of aerosols with diameter 0.3 – 10 µm are elevated by the presence of the patient with no HFNC flow, relative to the room far-field, by 0.45 #/cm3. While we observed variability between subjects in their emission and dispersion of particles, we did not find an association between HFNC and near-field elevations of particle counts.
Conclusion Near-patient levels of particles with diameter in the 0.3-10 µm range was not affected by the use of HFNC in healthy patients. Further study on older children and children with increased mucus production may be warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Doernbecher Philanthropy Board provided funding for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Oregon Health & Science University IRB approved this study as human subjects research. All parents provided written consent to participate.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source: The Doernbecher Philanthropy Board provided funding for the study.
Financial disclosure: The authors have indicated they have no financial relationships relevant to this article to disclose.
Conflict of interest statement: The authors have indicated they have no potential conflicts of interest to disclose.
Data sharing statement: Deidentified individual participant data will not be made available. Measurements of constituents in air made in participant rooms will be made available upon reasonable request.
Ms. Laguerre contributed to the study design, was the primary data collector, contributed to the analysis and writing the manuscript.
Dr. Noelck contributed to the study design, execution of the study and revised the manuscript.
Dr. Van Meurs contributed to the recruitment, data collection and revised the manuscript.
Dr. Austin contributed to the study design and revised the manuscript.
Dr. Foster contributed to the study conception, design, recruitment, data collection and drafting the manuscript.
Data Availability
Deidentified individual participant data will not be made available. Measurements of constituents in air made in participant rooms will be made available upon reasonable request.
